Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Document type

Article

Version

Published version

Publication date

Publication license

cc by-nc-nd (c) Elsevier, 2024
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/207222

Clinical Implications of Genomic Profile in Waldenström Macroglobulinemia

Journal Title

Director/Tutor

Journal ISSN

Volume Title

Abstract

With the increasing availability of sequencing techniques and new polymerase chain reaction-based methods, data regarding the genomic profile of Waldenström macroglobulinemia (WM) are being continuously analyzed and reproduced. MYD88 and CXCR4 mutations are highly prevalent in all the stages of WM, including the early IgM monoclonal gammopathy of undetermined significance or a more advanced stage, such as smoldering WM. Thus, there is a need to define genotypes before starting either standard treatment regimens or clinical trials. Here, we review the genomic profile of WM and its clinical implications while focusing on recent advances.Copyright © 2023 Elsevier Inc. All rights reserved.

Subject (English)

Citation

Citation

MORENO FAJARDO, David Fernando and FERNÁNDEZ DE LARREA RODRÍGUEZ, Carlos José. Clinical Implications of Genomic Profile in Waldenström Macroglobulinemia. Hematology-Oncology Clinics Of North America. 2023. Vol. 37, num. 4, pags. 659-670. ISSN 0889-8588. [consulted: 12 of August of 2026]. Available at: https://hdl.handle.net/2445/207222

Export metadata

JSON - METS

Share record